Siemens Healthineers Sinks to Six-Year Low as Sector Contagion Compounds Existing Woes

Siemens Healthineers shares plunge to €34.00 as US peer GE HealthCare’s profit warning sparks sector-wide contagion, with China austerity and spin-off delay adding pressure.

The medical technology sector is learning a painful lesson in contagion. Siemens Healthineers hit a fresh six-year trough of €34.00 on Wednesday, dragged down not by its own missteps but by a brutal sell-off in US peer GE HealthCare. The American rival cratered as much as 14 percent after posting disappointing quarterly earnings and slashing its full-year profit forecast, now seeing adjusted earnings per share of $4.80 to $5.00 versus an earlier range of $4.95 to $5.15. The culprit: a $250 million cost headwind from surging prices for memory chips, energy, and transport.

The market’s message was clear — if GE HealthCare can’t dodge these input cost pressures, neither can anyone else. And Siemens Healthineers, already wrestling with its own slate of challenges, has little room for error.

China headwinds and domestic austerity pile on

The German group’s first-quarter numbers for fiscal 2026 told a story of modest top-line growth masking deeper strain. Revenue edged up 3.8 percent, but adjusted earnings per share slipped to €0.49 — a 3 percent year-on-year decline. The diagnostics division is bearing the brunt of a Chinese anti-corruption campaign that has centralised procurement and stalled purchasing decisions. That drag is expected to persist into the second quarter, where analysts forecast EPS of €0.51, down from €0.56 a year earlier, with revenue flat at around €5.9 billion.

Beyond China, the headwinds are stacking up. Planned austerity measures in Germany’s healthcare system are clouding the domestic outlook, while new US tariffs are expected to weigh on EBIT by roughly €400 million. Currency effects add another €250 million in negative translation. The company is standing by its full-year guidance of comparable revenue growth of 5 to 6 percent and adjusted EPS of €2.20 to €2.40, but the May 7 second-quarter release will be a critical test of whether those targets hold.

Spin-off delay removes a near-term catalyst

Compounding the operational pressure is a structural overhang. Siemens AG, which still holds around 67 percent of Healthineers, has pushed back the planned spin-off of a 30 percent stake to its shareholders. The vote will now take place at the annual general meeting in February 2027, dashing hopes of a 2026 execution. Regulatory hurdles remain unresolved, and the parent’s €13.9 billion in debt guarantees would need to be replaced by standalone financing post-separation.

The delay strips the stock of a key valuation support. Many investors had viewed the spin-off as a catalyst to unlock value and broaden the free float, potentially drawing in a wider investor base. Instead, they face a prolonged wait, with the shares trading barely above their 52-week low of €33.80.

Analyst optimism clashes with market reality

Despite the carnage, the analyst community remains firmly constructive. JPMorgan’s David Adlington reiterated his “Overweight” rating with a €61.30 target, arguing that most of the bad news is already priced in. Barclays is also overweight, albeit with a more conservative €55 target. Even that lower figure implies roughly 60 percent upside from the current price of €34.46.

The stock’s relative strength index has fallen to 28.6, deep in oversold territory. But with near-term catalysts scarce and the GE HealthCare shadow still fresh, the market is demanding proof before it buys the dip. The May 7 numbers will need to show that Siemens Healthineers can absorb cost pressures better than its US rival — and that China is showing early signs of stabilisation. Until then, the disconnect between analyst conviction and share price reality looks set to persist.